Somewhat Positive Press Coverage Somewhat Unlikely to Impact Enzo Biochem (ENZ) Share Price
Press coverage about Enzo Biochem (NYSE:ENZ) has trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Enzo Biochem earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 43.4714580007623 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Uveitis Treatment Market to Exhibit a Healthy Growth of 7.3% CAGR Between 2014-2020 (sbwire.com)
- Global Healthcare Biomarkers Market Size will Exceed US$ 56 Billion By 2022 (marketwatch.com)
- Global Human Papillomavirus (HPV) Testing Market to Exhibit a Healthy Growth of 7.6% CAGR Between 2017-2025 (sbwire.com)
- Relative Strength Alert For Enzo Biochem (marketnewsvideo.com)
- Protein Labeling Market to Develop Rapidly by 2025 (reports.pr-inside.com)
Enzo Biochem (ENZ) opened at $9.10 on Friday. Enzo Biochem has a twelve month low of $6.27 and a twelve month high of $12.04.
Several brokerages have recently commented on ENZ. BidaskClub lowered Enzo Biochem from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Zacks Investment Research lowered Enzo Biochem from a “buy” rating to a “hold” rating in a report on Tuesday, August 15th. Finally, TheStreet lowered Enzo Biochem from a “b” rating to a “c+” rating in a report on Wednesday, September 27th.
In related news, EVP James Michael O’brien sold 22,866 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The stock was sold at an average price of $10.28, for a total value of $235,062.48. Following the completion of the sale, the executive vice president now owns 34,886 shares in the company, valued at approximately $358,628.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gregory M. Bortz sold 42,005 shares of the business’s stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $9.82, for a total value of $412,489.10. Following the completion of the sale, the director now owns 292,875 shares of the company’s stock, valued at approximately $2,876,032.50. The disclosure for this sale can be found here. Insiders sold a total of 191,398 shares of company stock valued at $1,925,292 in the last 90 days. 9.50% of the stock is currently owned by corporate insiders.
Enzo Biochem Company Profile
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Stock Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related stocks with our FREE daily email newsletter.